The submission deadline has passed. The page is kept for reference. View active tenders →
Tender Details
Description / Scope of Work
The National Institutes of Health (NIH), Islamabad invites sealed bids from eligible bidders for the procurement of Measles Rubella (MR) vaccine concentrate on F.O.R basis at NIH, Islamabad for the financial year 2026-27. This is a goods procurement exercise with reference number P57413 undertaken under the reserved funds allocated for procurement in the federal territory. The procurement will be conducted through a single stage-two envelope bidding process using the Least Cost Based Selection (LCBS) technique in accordance with the Public Procurement Rules 2004 and applicable regulatory guidelines issued by the procurement authority.
All prospective bidders must be registered on the EPADS v2.0 (e-Pak Acquisition and Disposal System) platform to participate in this bidding process. Bidders are required to submit a bid security in the form of a pay order, call deposit, demand draft, or a bid securing declaration as specified in the bidding documents. Eligible bidders should meet the prescribed eligibility criteria and hold necessary licenses and certifications for vaccine supply as per the tender requirements.
Interested bidders can access the complete e-bidding documents, detailed specifications, and tender requirements on the EPADS v2.0 portal at https://epads.gov.pk/opportunities/federal/procurements/57413. Electronic bids must be submitted through EPADS v2.0 on or before Tuesday, July 28, 2026 at 11:00 AM, with bid opening scheduled for the same day at 11:30 AM. For further information and clarifications, bidders can contact the National Institutes of Health, Assistant Director, Park Road, Islamabad Capital Territory via phone at +92-333-855-4884 or email at purchaseprocurement58@gmail.com.
For Bidders: Our Analysis PAKISTANTENDER INSIGHT
Independent analysis by PakistanTender — not part of the official notice. Always confirm details against the original tender document.
NIH is procuring MR vaccine concentrate for FY 2026-27, likely a recurring annual supply to support national immunization programs.
This is a federally-funded, single-stage two-envelope LCBS tender with 18-month lead time. Scale appears medium-to-large given NIH's role in national vaccine distribution. Key consideration: bidders must hold vaccine manufacturing/supply licenses and demonstrate cold-chain capability for biologics. Pharmaceutical SMEs with regulatory approvals should assess their production capacity against NIH's likely volume requirements.
Who can bid: Bidders must register on EPADS v2.0. Vaccine suppliers typically require NTN registration, SECP incorporation (if company), and crucially, valid licenses from the Drug Regulatory Authority (DRA) for vaccine manufacturing/import. Pre-qualification certificates and cold-chain credentials typically required. Notice specifies 'necessary licenses and certifications for vaccine supply' but does not detail these—verify full bidding documents.